Read more:
Bone Therapeutics provides fourth quarter 2020 business update and 2021 outlook
Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032
PAOG Announces Plans To Add New Pharmaceutical Product Developments
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
Genovac Purchases Third Beacon® Optofluidic System and Expands its Capabilities into Cell Line Development
Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021
Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association…
CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference
See the original post:
CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference
Bone Therapeutics Provides First Quarter 2021 Business Update
Continue reading here:
Bone Therapeutics Provides First Quarter 2021 Business Update
Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
See the article here:
Prometheus Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week
PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021
Orchard Therapeutics Announces $150 Million Strategic Financing
Read the original:
Orchard Therapeutics Announces $150 Million Strategic Financing